AAPL333.27+1.93 (+0.58%) ▲|ABBV263.03-0.02 (-0.01%) ▼|ABT103.08+1.05 (+1.03%) ▲|ACN191.47-1.93 (-1.00%) ▼|ADBE252.20-5.56 (-2.16%) ▼|AMAT418.79-2.38 (-0.57%) ▼|AMD521.24+17.04 (+3.38%) ▲|AMGN378.02+2.37 (+0.63%) ▲|AMT178.53+0.82 (+0.46%) ▲|AMZN247.49-0.93 (-0.37%) ▼|AVGO339.62+0.35 (+0.10%) ▲|AXP317.26-7.17 (-2.21%) ▼|BA209.74+0.05 (+0.02%) ▲|BAC58.48-1.05 (-1.76%) ▼|BKNG172.80+1.48 (+0.86%) ▲|BLK1,052.47-6.19 (-0.58%) ▼|BMY64.04+0.31 (+0.49%) ▲|BNY155.89+1.22 (+0.79%) ▲|BRK-B521.22+4.46 (+0.86%) ▲|C135.44-0.74 (-0.54%) ▼|CAT790.35+6.81 (+0.87%) ▲|CL87.54+0.54 (+0.62%) ▲|CMCSA24.08-0.34 (-1.39%) ▼|COF207.25+0.40 (+0.19%) ▲|COP134.42-6.81 (-4.82%) ▼|COST899.94-1.41 (-0.16%) ▼|CRM251.26-4.39 (-1.72%) ▼|CSCO110.75+0.68 (+0.61%) ▲|CVS93.13-1.36 (-1.44%) ▼|CVX212.97-4.80 (-2.20%) ▼|DE672.68-11.36 (-1.66%) ▼|DHR209.64+0.28 (+0.13%) ▲|DIS107.90+1.48 (+1.39%) ▲|DUK118.05+0.28 (+0.23%) ▲|EMR147.94+0.94 (+0.64%) ▲|FDX304.44-3.82 (-1.24%) ▼|GD361.16+2.56 (+0.71%) ▲|GE317.16+10.11 (+3.29%) ▲|GEV925.48+42.67 (+4.83%) ▲|GILD148.48+2.18 (+1.49%) ▲|GM84.70-0.67 (-0.78%) ▼|GOOG341.68+0.25 (+0.07%) ▲|GOOGL344.99+0.01 (+0.00%) ▲|GS983.39+6.72 (+0.69%) ▲|HD308.08+2.60 (+0.85%) ▲|HON207.74+4.30 (+2.11%) ▲|IBM240.35-8.02 (-3.23%) ▼|INTC101.41+4.27 (+4.40%) ▲|INTU322.49-6.78 (-2.06%) ▼|ISRG383.12+5.96 (+1.58%) ▲|JNJ267.62+0.42 (+0.16%) ▲|JPM351.40-1.09 (-0.31%) ▼|KO88.42-0.29 (-0.33%) ▼|LIN464.06+1.10 (+0.24%) ▲|LLY1,139.22+3.11 (+0.27%) ▲|LMT537.67+4.21 (+0.79%) ▲|LOW197.16+2.55 (+1.31%) ▲|LRCX270.44-0.43 (-0.16%) ▼|MA569.49-3.78 (-0.66%) ▼|MCD251.63-1.15 (-0.45%) ▼|MDLZ62.67+0.57 (+0.91%) ▲|MDT93.32-0.44 (-0.46%) ▼|META675.12+4.88 (+0.73%) ▲|MMM163.51-1.16 (-0.70%) ▼|MO70.52+0.71 (+1.01%) ▲|MRK144.43+0.64 (+0.44%) ▲|MS207.93+1.65 (+0.80%) ▲|MSFT493.57-3.56 (-0.72%) ▼|MU931.24+3.64 (+0.39%) ▲|NEE80.65-0.43 (-0.52%) ▼|NFLX77.14-0.77 (-0.98%) ▼|NKE36.36+0.14 (+0.39%) ▲|NOW141.21-0.69 (-0.49%) ▼|NVDA214.97+2.80 (+1.32%) ▲|ORCL143.12+2.77 (+1.97%) ▲|PEP135.33-0.17 (-0.13%) ▼|PFE27.53-0.03 (-0.09%) ▼|PG148.07+1.40 (+0.95%) ▲|PLTR172.65+0.09 (+0.05%) ▲|PM193.58-0.54 (-0.28%) ▼|QCOM187.28-0.52 (-0.28%) ▼|RTX197.49+1.99 (+1.02%) ▲|SBUX97.90+1.32 (+1.36%) ▲|SCHW105.69-2.10 (-1.95%) ▼|SO86.47+0.52 (+0.60%) ▲|SPG203.77-0.33 (-0.16%) ▼|T26.18-0.54 (-2.02%) ▼|TMO648.70+7.31 (+1.14%) ▲|TMUS177.45-3.02 (-1.67%) ▼|TSLA360.47+3.89 (+1.09%) ▲|TXN264.81+1.38 (+0.52%) ▲|UBER71.65+0.22 (+0.31%) ▲|UNH378.31+2.38 (+0.63%) ▲|UNP283.40-0.60 (-0.21%) ▼|UPS99.60-2.75 (-2.69%) ▼|USB61.29-0.93 (-1.49%) ▼|V371.07-4.55 (-1.21%) ▼|VZ50.37-1.09 (-2.11%) ▼|WFC88.70-1.02 (-1.14%) ▼|WMT108.53+0.44 (+0.40%) ▲|XOM164.80-4.52 (-2.67%) ▼|AAPL333.27+1.93 (+0.58%) ▲|ABBV263.03-0.02 (-0.01%) ▼|ABT103.08+1.05 (+1.03%) ▲|ACN191.47-1.93 (-1.00%) ▼|ADBE252.20-5.56 (-2.16%) ▼|AMAT418.79-2.38 (-0.57%) ▼|AMD521.24+17.04 (+3.38%) ▲|AMGN378.02+2.37 (+0.63%) ▲|AMT178.53+0.82 (+0.46%) ▲|AMZN247.49-0.93 (-0.37%) ▼|AVGO339.62+0.35 (+0.10%) ▲|AXP317.26-7.17 (-2.21%) ▼|BA209.74+0.05 (+0.02%) ▲|BAC58.48-1.05 (-1.76%) ▼|BKNG172.80+1.48 (+0.86%) ▲|BLK1,052.47-6.19 (-0.58%) ▼|BMY64.04+0.31 (+0.49%) ▲|BNY155.89+1.22 (+0.79%) ▲|BRK-B521.22+4.46 (+0.86%) ▲|C135.44-0.74 (-0.54%) ▼|CAT790.35+6.81 (+0.87%) ▲|CL87.54+0.54 (+0.62%) ▲|CMCSA24.08-0.34 (-1.39%) ▼|COF207.25+0.40 (+0.19%) ▲|COP134.42-6.81 (-4.82%) ▼|COST899.94-1.41 (-0.16%) ▼|CRM251.26-4.39 (-1.72%) ▼|CSCO110.75+0.68 (+0.61%) ▲|CVS93.13-1.36 (-1.44%) ▼|CVX212.97-4.80 (-2.20%) ▼|DE672.68-11.36 (-1.66%) ▼|DHR209.64+0.28 (+0.13%) ▲|DIS107.90+1.48 (+1.39%) ▲|DUK118.05+0.28 (+0.23%) ▲|EMR147.94+0.94 (+0.64%) ▲|FDX304.44-3.82 (-1.24%) ▼|GD361.16+2.56 (+0.71%) ▲|GE317.16+10.11 (+3.29%) ▲|GEV925.48+42.67 (+4.83%) ▲|GILD148.48+2.18 (+1.49%) ▲|GM84.70-0.67 (-0.78%) ▼|GOOG341.68+0.25 (+0.07%) ▲|GOOGL344.99+0.01 (+0.00%) ▲|GS983.39+6.72 (+0.69%) ▲|HD308.08+2.60 (+0.85%) ▲|HON207.74+4.30 (+2.11%) ▲|IBM240.35-8.02 (-3.23%) ▼|INTC101.41+4.27 (+4.40%) ▲|INTU322.49-6.78 (-2.06%) ▼|ISRG383.12+5.96 (+1.58%) ▲|JNJ267.62+0.42 (+0.16%) ▲|JPM351.40-1.09 (-0.31%) ▼|KO88.42-0.29 (-0.33%) ▼|LIN464.06+1.10 (+0.24%) ▲|LLY1,139.22+3.11 (+0.27%) ▲|LMT537.67+4.21 (+0.79%) ▲|LOW197.16+2.55 (+1.31%) ▲|LRCX270.44-0.43 (-0.16%) ▼|MA569.49-3.78 (-0.66%) ▼|MCD251.63-1.15 (-0.45%) ▼|MDLZ62.67+0.57 (+0.91%) ▲|MDT93.32-0.44 (-0.46%) ▼|META675.12+4.88 (+0.73%) ▲|MMM163.51-1.16 (-0.70%) ▼|MO70.52+0.71 (+1.01%) ▲|MRK144.43+0.64 (+0.44%) ▲|MS207.93+1.65 (+0.80%) ▲|MSFT493.57-3.56 (-0.72%) ▼|MU931.24+3.64 (+0.39%) ▲|NEE80.65-0.43 (-0.52%) ▼|NFLX77.14-0.77 (-0.98%) ▼|NKE36.36+0.14 (+0.39%) ▲|NOW141.21-0.69 (-0.49%) ▼|NVDA214.97+2.80 (+1.32%) ▲|ORCL143.12+2.77 (+1.97%) ▲|PEP135.33-0.17 (-0.13%) ▼|PFE27.53-0.03 (-0.09%) ▼|PG148.07+1.40 (+0.95%) ▲|PLTR172.65+0.09 (+0.05%) ▲|PM193.58-0.54 (-0.28%) ▼|QCOM187.28-0.52 (-0.28%) ▼|RTX197.49+1.99 (+1.02%) ▲|SBUX97.90+1.32 (+1.36%) ▲|SCHW105.69-2.10 (-1.95%) ▼|SO86.47+0.52 (+0.60%) ▲|SPG203.77-0.33 (-0.16%) ▼|T26.18-0.54 (-2.02%) ▼|TMO648.70+7.31 (+1.14%) ▲|TMUS177.45-3.02 (-1.67%) ▼|TSLA360.47+3.89 (+1.09%) ▲|TXN264.81+1.38 (+0.52%) ▲|UBER71.65+0.22 (+0.31%) ▲|UNH378.31+2.38 (+0.63%) ▲|UNP283.40-0.60 (-0.21%) ▼|UPS99.60-2.75 (-2.69%) ▼|USB61.29-0.93 (-1.49%) ▼|V371.07-4.55 (-1.21%) ▼|VZ50.37-1.09 (-2.11%) ▼|WFC88.70-1.02 (-1.14%) ▼|WMT108.53+0.44 (+0.40%) ▲|XOM164.80-4.52 (-2.67%) ▼|
25.8 C
New York
Wednesday, September 16, 2026

Tag: analysis

newssourceFORcompanyinformationcontent1releasesmarket

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

Jason Yang and Ruoqi Li Featured In XYZ Media’s “Next Generation of Innovators” Series for Developing an AI-Driven Multimodal Model Advancing Elderly Fall Risk...

LOS ANGELES, June 22, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is proud to announce the latest feature in its “Next Generation of Innovators” series, a digital campaign celebrating extraordinary young minds developing innovative solutions to global challenges. The latest series highlights two exceptional student researchers - Jason Yang of Head-Royce School in Oakland, CA, and Ruoqi Li of The Harker School in San Jose, CA - for their novel work in developing a multimodal machine learning framework that accurately assesses fall risk among the elderly using sensors, video, and contextual data.

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular...

Trump, Munir exchange praises as Pakistan rises as regional stabilizer: IRS Analysis

The Institute of Regional Studies in Islamabad has analyzed the engagement between Trump and Asim Munir - shared insights about potential windfalls for Pak

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAnalysis

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers